Abstract
Budesonide/glycopyrronium/formoterol fumarate dihydrate 320/14.4/10 μg (BGF) triple therapy is approved as maintenance treatment in patients with moderate-to-very severe chronic obstructive pulmonary disease (COPD) in the European Union. In a published network meta-analysis (Bourdin et al. Adv Ther 2021:38;3089–3112), BGF demonstrated comparable efficacy to other fixed-dose combination therapies and open-triple combinations in terms of exacerbation rate reductions. This study aimed to evaluate the cost impact of BGF entry on the Italian healthcare system for managing this patient population.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have